Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 0 results

Large-scale testing (Phase 3)Study completedNCT00878709
What this trial is testing

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 2,840
Large-scale testing (Phase 3)Active Not RecruitingNCT04290793
What this trial is testing

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 113
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Early research (Phase 1)Looking for participantsNCT06139107
What this trial is testing

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Who this might be right for
Breast Cancer
Mridula George, MD 15
Testing effectiveness (Phase 2)Looking for participantsNCT07102381
What this trial is testing

Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer
Jazz Pharmaceuticals 125
Large-scale testing (Phase 3)WithdrawnNCT03658213
What this trial is testing

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Who this might be right for
Breast Cancer
AstraZeneca
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07795424
What this trial is testing

Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer

Who this might be right for
Breast CancerHR Positive, HER2 Positive Breast Cancer
Shengjing Hospital 33
Not applicableLooking for participantsNCT06446882
What this trial is testing

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast Cancer
Fundacio Clinic Barcelona 304
Not applicableActive Not RecruitingNCT04118192
What this trial is testing

NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer

Who this might be right for
Breast Cancer
University of Birmingham 72
Not applicableLooking for participantsNCT06328465
What this trial is testing

FREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

Who this might be right for
Invasive Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer
European Institute of Oncology 145
Testing effectiveness (Phase 2)Looking for participantsNCT06259929
What this trial is testing

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Fondazione Oncotech 51
Not applicableActive Not RecruitingNCT04854005
What this trial is testing

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 78
Not applicableWithdrawnNCT03080428
What this trial is testing

Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer

Who this might be right for
ER-positive Her2-negative Early Breast Cancer
UNICANCER